#China #Shanghai #Clinical Trials #Ribo Life Science #Vortosiran

Positive Phase 2a Trial Results for Vortosiran: A New Hope for Patients

Suzhou Ribo Life Science Co., Ltd., alongside its subsidiary Ribocure Pharmaceuticals AB, has unveiled promising results from a Phase 2a clinical trial of Vortosiran, a novel pARNi-based treatment targeting factor XI in patients suffering from coronary artery disease. At the recent China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the company highlighted the drug's ability to significantly inhibit factor XI, signifying a major advancement in antithrombotic therapies.

This randomized, double-blind, placebo-controlled study aimed to determine the drug's efficacy and safety in subjects already undergoing standard aspirin therapy. Findings reveal that Vortosiran was well-tolerated, showing a notable, dose-dependent inhibition of factor XI activity. Patients receiving the high-dose regimen, which included a maintenance dose of 400 mg, experienced an impressive 92% reduction in factor XI activity that persisted for several months post-administration, suggesting the possibility of less frequent dosing schedules of every three to six months.

What sets Vortosiran apart is not only its strong inhibition rates but also the absence of serious adverse events linked to the treatment. Unlike conventional anticoagulants that often carry a risk of bleeding complications, this innovative approach seeks to minimize thrombotic risks while ensuring hemostasis is preserved.

Dr. Li-Ming Gan, co-CEO and Global Head of R&D at Ribo, expressed optimism about these results, stating that the Phase 2a data firmly supports Vortosiran as a safe, differentiated option for inhibiting factor XI in treating thromboembolic diseases. He emphasized, "Preventing blood clot formation without increasing bleeding risk has long been the ultimate goal of cardiovascular medicine. This data reinforces our belief that Vortosiran represents a highly promising approach to factor XI inhibition."

The Vortosiran Advantage

Vortosiran (RBD4059) is a pARNi candidate derived from the proprietary RiboGalSTAR™ platform, designed to selectively inhibit the synthesis of factor XI. This mechanism of action targets the intrinsic pathway of coagulation, showcasing its potent antithrombotic properties. Human genetic studies reinforce this approach, indicating that individuals with naturally low levels of factor XI are protected against thrombotic diseases without an accompanying rise in spontaneous bleeding risks. As such, targeting factor XI emerges as a highly acceptable therapeutic avenue, striking a balance between effective thrombosis prevention and enhanced safety relative to current anticoagulants.

Exciting Next Steps

In light of these groundbreaking findings, Ribo has initiated the ORBIT-XI program—Optimizing RNA-Based Inhibition of Thrombosis—encompassing several Phase 2b trials. These efforts are geared towards facilitating a swift transition to Phase 3 clinical development for multiple indications.

In summary, the Phase 2a results for Vortosiran mark a significant milestone in the search for improved antithrombotic therapies. Patients battling coronary artery disease may soon have access to a revolutionary treatment that effectively combats clotting while ensuring safety. Ribo Life Science's dedication to exploring novel drug delivery methods and therapeutic targets continues to pave the way for breakthroughs in the field of cardiovascular medicine. For further details and updates, visit Ribo Life Science and Ribocure Pharmaceuticals.